Researchers working to turn fish heads, bones into good food
Humans directly consume about 35% of all seafood harvests with the rest going to lower value uses
BlueNalu promotes first employee Madden to CTO
Madden joined BlueNalu in 2018 as its first employee and has been instrumental in developing technology strategy while also leading the research and development team
Thai university study: Calysta shrimp feed cuts EMS deaths
Since its discovery in 2009, early mortality syndrome has reduced the harvests of shrimp in some regions of China by as much as 80%
Investment in seafood alternatives climb even as challenges remain
Investments in seafood 'alternatives' continue to climb despite the pandemic, with a 23% increase in sales, but the industry is still small and facing many challenges
Irish firm hooks up with IndieBio for help with US seaweed venture
Plantruption continues to work to expand the use of seaweed as a meat substitute, pairing with IndieBio in a drive toward a US launch.
Nomad, cell-based seafood firm BlueNalu ink Europe distribution deal
The UK's Nomad Foods, owner of the Iglo and Birds Eye brands, has signed a deal with US cell-based seafood producer BlueNalu to sell products in Europe
Calysta promises ‘transformational’ results for shrimp industry after Thai Union study
Calysta, one of the frontrunners in developing an alternative protein, says an upcoming study will demonstrate ‘transformational’ results for the Asian shrimp industry
Vinh Hoan, CJ invest in cell-based shrimp startup Shiok Meats
As well as Vinh Hoan, South Korean food groups Woowa Brothers Asia Holdings and CJ CheilJedang also invested in the round
Ingredient cost still a bottleneck for fish-free shrimp feed adoption
Major aquafeed firms and shrimp producers said the commercial market is still not ready for complete fish-free shrimp feeds as the cost of alternative ingredients remain high
Thai Union involved in cultivated meat firm’s $105m series B round
Aleph Farms, a cultivated meat company growing steaks directly from non-genetically modified animal cells, has announced the completion of a $105m series B funding round